{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T20:20:53Z","timestamp":1772050853291,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.lungcan.2019.02.001","type":"journal-article","created":{"date-parts":[[2019,2,2]],"date-time":"2019-02-02T10:32:42Z","timestamp":1549103562000},"page":"42-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapy"],"prefix":"10.1016","volume":"130","author":[{"given":"Haixia","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yabo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guowei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuanxuan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinbo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2019.02.001_bib0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.lungcan.2019.02.001_bib0010","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/1759-7714.12169","article-title":"Epidemiology of lung cancer in China","volume":"6","author":"Chen","year":"2007","journal-title":"Thorac. Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2019.02.001_bib0015","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non\u2013small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2019.02.001_bib0020","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.canep.2015.02.003","article-title":"Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: the Spanish REASON study","volume":"39","author":"Rapp","year":"2015","journal-title":"Cancer Epidemiol."},{"issue":"6","key":"10.1016\/j.lungcan.2019.02.001_bib0025","first-page":"2841","article-title":"Primary and secondary resistance to tyrosine kinase inhibitors in lung cancer","volume":"34","author":"Simasi","year":"2014","journal-title":"Anticancer Res."},{"issue":"350","key":"10.1016\/j.lungcan.2019.02.001_bib0030","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2019.02.001_bib0035","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2019.02.001_bib0040","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.lungcan.2014.11.013","article-title":"Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR mutated non-small cell lung cancer except both exon 19 deletion and exon 21L858R: a retrospective analysis in Korea","volume":"87","author":"Baek","year":"2015","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2019.02.001_bib0045","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/JTO.0000000000000504","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X\/L861Q\/S768I mutations","volume":"10","author":"Chiu","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"24","key":"10.1016\/j.lungcan.2019.02.001_bib0050","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.2011.41.2056","article-title":"First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: The TORCH randomized trial","volume":"30","author":"Gridelli","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2019.02.001_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2018.01.005","article-title":"Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: long-term follow-up of a large patient cohort","volume":"117","author":"Okamoto","year":"2018","journal-title":"Lung Cancer"},{"issue":"18","key":"10.1016\/j.lungcan.2019.02.001_bib0060","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1200\/JCO.2013.52.4694","article-title":"Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: docetaxel and erlotinib lung cancer trial (DELTA)","volume":"32","author":"Tomoya","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2019.02.001_bib0065","article-title":"Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations","author":"Cheng","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"Februatry","key":"10.1016\/j.lungcan.2019.02.001_bib0070","first-page":"6","article-title":"Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation","volume":"128","author":"Xiangtao","year":"2019","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2019.02.001_bib0075","doi-asserted-by":"crossref","first-page":"543","DOI":"10.21147\/j.issn.1000-9604.2017.06.09","article-title":"Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinumbased chemotherapy","volume":"29","author":"Jinpeng","year":"2017","journal-title":"Chin. J. Cancer Res."},{"issue":"11","key":"10.1016\/j.lungcan.2019.02.001_bib0080","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1158\/1078-0432.CCR-10-3408","article-title":"Effectiveness of tyrosine kinase inhibitors on \"uncommon\" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer","volume":"17","author":"Wu","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.lungcan.2019.02.001_bib0085","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.lungcan.2014.12.009","article-title":"The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer","volume":"87","author":"Arrieta","year":"2015","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.lungcan.2019.02.001_bib0090","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","article-title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR, mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2019.02.001_bib0095","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/sj.onc.1209159","article-title":"Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants","volume":"25","author":"Chen","year":"2006","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.lungcan.2019.02.001_bib0100","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/JTO.0b013e3182021f3e","article-title":"The epidermal growth factor receptor-L861Q mutation increases kinase activity without leading to enhanced sensitivity toward epidermal growth factor receptor kinase inhibitors","volume":"6","author":"Kancha","year":"2011","journal-title":"J. Thorac. Oncol."},{"issue":"19","key":"10.1016\/j.lungcan.2019.02.001_bib0105","doi-asserted-by":"crossref","first-page":"8968","DOI":"10.1158\/0008-5472.CAN-05-1829","article-title":"Epidermal growth factor-independent transformation of Ba\/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression","volume":"65","author":"Jiang","year":"2005","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2019.02.001_bib0110","doi-asserted-by":"crossref","first-page":"18","DOI":"10.21147\/j.issn.1000-9604.2017.01.03","article-title":"Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations","volume":"29","author":"Zhang","year":"2017","journal-title":"Chinese J. Cancer Res."},{"issue":"2","key":"10.1016\/j.lungcan.2019.02.001_bib0115","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/JTO.0000000000000048","article-title":"Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q","volume":"9","author":"Watanabe","year":"2014","journal-title":"J. Thorac. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950021930306X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950021930306X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T04:06:02Z","timestamp":1555041962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016950021930306X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":23,"alternative-id":["S016950021930306X"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.02.001","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapy","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}